The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
LRRC15-radioimmunotheranostics: Targeting TGFß-driven resistance in immune-excluded solid tumors.
 
H David S Ulmert
Leadership - DiaProst
Stock and Other Ownership Interests - DiaProst
Consulting or Advisory Role - Curium Pharma; Molecular Partners; Radiopharm Theranostics
Research Funding - Janssen Research & Development (Inst); Lantheus Medical Imaging (Inst); Radiopharm Theranostics (Inst)
Patents, Royalties, Other Intellectual Property - hK2 mAb technology; KLK3 mAb technology; LRRC15-RIT (Inst); PRAME mAb technology (Inst)
Travel, Accommodations, Expenses - Curium Pharma; Lantheus Medical Imaging; Radiopharm Theranostics
 
Mohamed Altai
Research Funding - Lantheus Medical Imaging (Inst)
 
Claire Storey
Patents, Royalties, Other Intellectual Property - LRRC15-RIT (Inst)
 
Michael Cheng
No Relationships to Disclose
 
Katharina Lückerath
Consulting or Advisory Role - SOFIE
 
Sumit Subudhi
Stock and Other Ownership Interests - Apricity Health
Consulting or Advisory Role - Amgen; Apricity Health; Arcus Biosciences,; AstraZeneca; Baird; Bayer; Boxer Capital; Breaking Data; Bristol-Myers Squibb; Cancer Expert Now; ChemoCentryx; Clinical Comms Group; Dava Oncology; Dendreon; Hervolution Therapeutics; InProTher Janssen; Kahr Medical Ltd; Kiniksa; MacroGenics; MacroGenics; MD Education; Merck; Novartis; OncLive (owned by Intellisphere, LLC); Pfizer; Polaris; Portage Biotech; Regeneron; Rondo
Research Funding - AstraZeneca; Bristol-Myers Squibb; Janssen; Regeneron
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Regeneron
 
Ken Herrmann
Leadership - Aktis Oncology; Pharma15
Stock and Other Ownership Interests - AdvanCell; Aktis Oncology; Convergent Therapeutics; SOFIE
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; AstraZeneca; Bain Capital; Bayer; Boston Scientific; BTG; Debiopharm Group; Fusion Pharmaceuticals; GE Healthcare; Immedica; IPSEN; ITG (Inst); Janssen Oncology; Molecular Partners; Novartis; Radiopharm Theranostics; ROTOP Pharmaka (Inst); Siemens Healthineers; Telix Pharmaceuticals
 
Wahed Zedan
No Relationships to Disclose
 
Julie Tran
No Relationships to Disclose
 
Julie Park
No Relationships to Disclose
 
Smiths Lueong
No Relationships to Disclose
 
Marija Trajkovic- Arsic
No Relationships to Disclose
 
Bilal Siddiqui
Research Funding - Regeneron (Inst)
 
Constance Yuen
No Relationships to Disclose
 
Laurent Bentolila
No Relationships to Disclose
 
Johannes Czernin
Leadership - SOFIE; Trethera
Stock and Other Ownership Interests - SOFIE; Trethera
Consulting or Advisory Role - Aktis Oncology; RayzeBio
 
Jens Siveke
Stock and Other Ownership Interests - FAPi Holding AG
Consulting or Advisory Role - AstraZeneca; AstraZeneca (Inst); Bayer; Bristol-Myers Squibb/Celgene; Falk Foundation; Immunocore; MCI Deutschland; MSD; MSD; Novartis; Roche; SERVIER
Research Funding - Abalos Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisbach Bio (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - SERVIER
 
Daniel Thorek
Stock and Other Ownership Interests - DiaProst
Consulting or Advisory Role - Curium Pharma
 
Xia Yang
No Relationships to Disclose
 
Robert Damoiseaux
Patents, Royalties, Other Intellectual Property - LRRC15-RIT (Inst)